Predictive Biomarker for Etanercept Response in RA

To assess whether mdNLR can be used as a predictive biomarker of response to the tumour necrosis factor inhibitor (TNFi) etanercept in RA, we used the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS) dataset, a prospective longitudinal study of response to biologic therapies in patients with RA. Illumina HumanMethylation 450K BeadChip array was used to generate DNA methylation data from pretreatment whole blood samples [21 (link)]. The DNA methylation dataset consisted of 36 very good responders (i.e., with clinical remission of their disease) and 35 nonresponders. Efficacy to TNFi was determined following 6 months on drug using established EULAR response criteria. The sample selection and preparation have been described previously [21 (link)]. Fifteen samples with missing information on smoking status were removed from the main analysis leaving 56 samples for the final analysis.

Free full text: Click here

Ambatipudi S., Sharp G.C., Clarke S.L., Plant D., Tobias J.H., Evans D.M., Barton A, & Relton C.L. (2018). Assessing the Role of DNA Methylation-Derived Neutrophil-to-Lymphocyte Ratio in Rheumatoid Arthritis. Journal of Immunology Research, 2018, 2624981.

Publication 2018

HumanMethylation 450K BeadChip array

Biologic therapies Biologics Biomarker Blood Dna methylation Drug Etanercept Patients Rheumatoid arthritis Tumour necrosis factor inhibitor

Corresponding Organization : University of Bristol

Other organizations : Bristol Royal Hospital for Children, NIHR Manchester Biomedical Research Centre, University of Manchester, Translational Research Institute, University of Queensland

Top 5 similar protocols

Variable analysis

independent variables

Smoking status

dependent variables

Response to the tumour necrosis factor inhibitor (TNFi) etanercept in RA

control variables

Pretreatment whole blood samples
Established EULAR response criteria for determining efficacy to TNFi after 6 months

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!